Kendra D. Tutsch

1.8k total citations
39 papers, 1.5k citations indexed

About

Kendra D. Tutsch is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Kendra D. Tutsch has authored 39 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Oncology, 13 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Kendra D. Tutsch's work include Cancer Treatment and Pharmacology (17 papers), Polyamine Metabolism and Applications (5 papers) and Chemotherapy-induced organ toxicity mitigation (5 papers). Kendra D. Tutsch is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Polyamine Metabolism and Applications (5 papers) and Chemotherapy-induced organ toxicity mitigation (5 papers). Kendra D. Tutsch collaborates with scholars based in United States, Spain and Germany. Kendra D. Tutsch's co-authors include Dona Alberti, George Wilding, Rhoda Arzoomanian, Rebecca Marnocha, Howard H. Bailey, Marcia Pomplun, Chris Feierabend, James P. Thomas, Kim Binger and Robert H. Earhart and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Clinical Cancer Research.

In The Last Decade

Kendra D. Tutsch

39 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kendra D. Tutsch United States 19 773 502 207 205 182 39 1.5k
Ramzi M. Mohammad United States 28 1.1k 1.4× 788 1.6× 249 1.2× 216 1.1× 175 1.0× 74 1.9k
Edward K. Han United States 26 1.2k 1.5× 764 1.5× 233 1.1× 165 0.8× 170 0.9× 32 1.9k
K D Tutsch United States 17 492 0.6× 544 1.1× 183 0.9× 161 0.8× 152 0.8× 22 1.4k
Wolfram C. M. Dempke Germany 20 727 0.9× 727 1.4× 258 1.2× 136 0.7× 397 2.2× 48 1.8k
Tsunekazu Kita Japan 24 876 1.1× 433 0.9× 222 1.1× 163 0.8× 190 1.0× 89 1.8k
Rhoda Arzoomanian United States 15 510 0.7× 319 0.6× 160 0.8× 139 0.7× 148 0.8× 27 947
Pulicat Manogaran Saudi Arabia 19 875 1.1× 499 1.0× 206 1.0× 276 1.3× 64 0.4× 35 1.6k
Clint Mitchell United States 30 1.6k 2.1× 846 1.7× 192 0.9× 174 0.8× 191 1.0× 43 2.5k
Alain De Pover Switzerland 16 1.2k 1.6× 341 0.7× 142 0.7× 192 0.9× 164 0.9× 25 1.6k
Adel Kardosh United States 19 424 0.5× 419 0.8× 135 0.7× 166 0.8× 142 0.8× 75 1.4k

Countries citing papers authored by Kendra D. Tutsch

Since Specialization
Citations

This map shows the geographic impact of Kendra D. Tutsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kendra D. Tutsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kendra D. Tutsch more than expected).

Fields of papers citing papers by Kendra D. Tutsch

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kendra D. Tutsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kendra D. Tutsch. The network helps show where Kendra D. Tutsch may publish in the future.

Co-authorship network of co-authors of Kendra D. Tutsch

This figure shows the co-authorship network connecting the top 25 collaborators of Kendra D. Tutsch. A scholar is included among the top collaborators of Kendra D. Tutsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kendra D. Tutsch. Kendra D. Tutsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Dy, Grace K., James P. Thomas, George Wilding, et al.. (2005). A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer. Clinical Cancer Research. 11(9). 3410–3416. 58 indexed citations
3.
Dubey, Sarita, Michael N. Gould, Kendra D. Tutsch, et al.. (2003). Phase I trial of perillyl alcohol administered four times daily continuously. Cancer Chemotherapy and Pharmacology. 52(5). 361–366. 21 indexed citations
4.
Liu, Glenn, Kurt R. Oettel, Howard H. Bailey, et al.. (2003). Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Investigational New Drugs. 21(3). 367–372. 45 indexed citations
5.
Liu, Glenn, Jordan Berlin, Kendra D. Tutsch, et al.. (2002). Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.. PubMed. 8(3). 706–11. 2 indexed citations
6.
Berlin, Jordan, Kendra D. Tutsch, Rhoda Arzoomanian, et al.. (2002). Phase I and pharmacokinetic study of a micronized formulation of carboxyamidotriazole, a calcium signal transduction inhibitor: toxicity, bioavailability and the effect of food.. PubMed. 8(1). 86–94. 16 indexed citations
7.
Thomas, James P., Kendra D. Tutsch, James F. Cleary, et al.. (2002). Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemotherapy and Pharmacology. 50(6). 465–472. 100 indexed citations
8.
Thomas, James, Rhoda Arzoomanian, Dona Alberti, et al.. (2001). Phase I clinical and pharmacokinetic trial of irofulven. Cancer Chemotherapy and Pharmacology. 48(6). 467–472. 16 indexed citations
9.
Carbone, Paul P., John D. Pirsch, James P. Thomas, et al.. (2001). Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants.. PubMed. 10(6). 657–61. 23 indexed citations
10.
Jacoby, Russell F., Carolyn E. Cole, Kendra D. Tutsch, et al.. (2000). Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.. PubMed. 60(7). 1864–70. 130 indexed citations
11.
Tutsch, Kendra D., Rhoda Arzoomanian, Dona Alberti, et al.. (1999). Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812). Investigational New Drugs. 17(1). 63–72. 23 indexed citations
12.
Robins, H. Ian, Kendra D. Tutsch, Elaine L. Jacobson, et al.. (1999). Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer. Journal of Clinical Oncology. 17(9). 2922–2922. 5 indexed citations
13.
Carbone, Paul P., Jeffrey A. Douglas, Paul O. Larson, et al.. (1998). Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine.. PubMed. 7(10). 907–12. 37 indexed citations
14.
McGinn, Cornelius J., et al.. (1995). 1041 Leucovorin (LV) modulation of iododeoxyuridine (IdUrd) radiosensitization; A phase I study. International Journal of Radiation Oncology*Biology*Physics. 32. 243–243. 2 indexed citations
15.
Hutson, Paul R., et al.. (1993). Evidence of an absorption phase after short intravenous suramin infusions. Cancer Chemotherapy and Pharmacology. 31(6). 495–499. 4 indexed citations
16.
Schiller, Joan H., et al.. (1993). Phase I trial of mitoxantrone and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced solid malignancies. Investigational New Drugs. 11(4). 291–300. 7 indexed citations
17.
Bailey, Howard H., George Wilding, Kendra D. Tutsch, et al.. (1992). A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions. Cancer Chemotherapy and Pharmacology. 30(4). 297–302. 2 indexed citations
18.
Buzaid, Antônio C., et al.. (1989). Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients. Cancer Chemotherapy and Pharmacology. 25(2). 124–130. 9 indexed citations
19.
Schiller, Joan H., et al.. (1989). Inadvertent administration of 480 mg/m2 of cisplatin. The American Journal of Medicine. 86(5). 624–625. 11 indexed citations
20.
Earhart, Robert H., et al.. (1983). Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat.. PubMed. 43(3). 1187–94. 58 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ramzi M. Mohammad Breakdown of academic impact, for papers by Edward K. Han Breakdown of academic impact, for papers by K D Tutsch Breakdown of academic impact, for papers by Wolfram C. M. Dempke Breakdown of academic impact, for papers by Tsunekazu Kita Breakdown of academic impact, for papers by Rhoda Arzoomanian Breakdown of academic impact, for papers by Pulicat Manogaran Breakdown of academic impact, for papers by Clint Mitchell Breakdown of academic impact, for papers by Alain De Pover Breakdown of academic impact, for papers by Adel Kardosh
Rankless by CCL
2026